Treatment of Overactive Bladder in the Older Patient: Pooled Analysis of Three Phase III Studies of Darifenacin, an M3 Selective Receptor Antagonist

The results demonstrate excellent efficacy, tolerability and safety with darifenacin 7.5 mg and 15 mg once-daily treatment for OAB in older patients.